Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSL101 in Wilson's Disease
NCT07240896Phase 1Recruiting
- Sponsor
- DSciLab
- Start
- Dec 2025
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of DSL101 in Wilson's disease, sponsored by DSciLab. Primary endpoint: Incidence of adverse events and serious adverse events at 56 weeks. Started Dec 2025; status: recruiting.
02
Drugs
DSL101
03
Conditions
Wilson's disease
Beyond the preview
Go deeper on NCT07240896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07240896.